Buccal Drug Delivery Systems: A Therapeutic Opportunity by Oral Route

Buccal drug delivery systems (BDDS) offer a number of therapeutic benefits for systemic drug delivery, making them a viable substitute for conventional oral dose forms. Bypassing the gastrointestinal tract and the liver's first-pass metabolism, these mechanisms allow medications to be absorbed through the buccal mucosa, increasing their bioavailability. BDDS are especially helpful for medications that are sensitive to gastrointestinal disorders, have a high first-pass metabolism, or are poorly absorbed. Compared to traditional oral formulations, the buccal mucosa's high vascularization enables quick and direct drug absorption into the systemic circulation, resulting in a quicker commencement of action. Modern formulation technologies, such as films, tablets, patches, and gels, have accelerated the development of buccal drug delivery systems by optimizing drug release and absorption. These systems improve patient compliance, especially when continuous drug administration is necessary, by providing controlled or sustained release profiles. Additionally, the buccal route makes administration simple and eliminates the necessity for swallowing, which makes it a good choice for patients who are dysphagic, elderly, or juvenile. For the wider clinical use of BDDS, however, issues such restricted drug penetration, mucosal irritation, and formulation stability must be resolved. Potential solutions for getting beyond these obstacles include the use of bioadhesive polymers, innovative excipients, and permeation enhancers. All things considered, buccal drug delivery devices offer a more efficient, practical, and patient-friendly method of oral drug administration, hence presenting substantial therapeutic prospects. Their clinical use in a variety of therapeutic domains will be improved by additional study and creativity.